Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. O-(5,6,7,8-tetrahydro-2-naphthyl)-6-methoxy-n-methylthio-2-pyridinecarbamate
1. 88678-31-3
2. Piritetrate
3. Liranaftate [inn]
4. Zefnart
5. M-732
6. Piritetrate;m-732
7. O-(5,6,7,8-tetrahydronaphthalen-2-yl) N-(6-methoxypyridin-2-yl)-n-methylcarbamothioate
8. 5253igo5x3
9. O-(5,6,7,8,-tetrahydro-2-naphthyl) 6-methoxy-n-methylthio-2-pyridinecarbamate
10. O-(5,6,7,8-tetrahydronaphthalen-2-yl) (6-methoxypyridin-2-yl)(methyl)carbamothioate
11. Ncgc00164601-01
12. Liranaftato
13. Liranaftatum
14. Dsstox_cid_26470
15. Dsstox_rid_81642
16. Dsstox_gsid_46470
17. Liranaftatum [inn-latin]
18. Liranaftato [inn-spanish]
19. O-(5,6,7,8-tetrahydro-2-naphthyl) N-(6-methoxy-2-pyridyl)-n-methylthiocarbamate
20. Cas-88678-31-3
21. Piritetate
22. Unii-5253igo5x3
23. Zefnart (tn)
24. M-732; Piritetrate
25. Liranaftate (jan/inn)
26. Liranaftate [mi]
27. Liranaftate [jan]
28. Liranaftate [mart.]
29. Liranaftate [who-dd]
30. Mls006011138
31. Schembl180466
32. Chembl1591365
33. Dtxsid6046470
34. Chebi:31775
35. Zinc13936
36. Glxc-25562
37. Hms3714a16
38. Act06298
39. Bcp11494
40. Hy-b0348
41. O-tetralin-6-yl N-(6-methoxy-2-pyridyl)-n-methyl-carbamothioate
42. Tox21 112223
43. Tox21_112223
44. Mfcd00865576
45. S1997
46. Akos015852015
47. Tox21_112223_1
48. Ab07498
49. Ac-3400
50. Ccg-220727
51. Ncgc00164601-02
52. Ncgc00164601-03
53. As-56279
54. Carbamothioic Acid, (6-methoxy-2-pyridinyl)methyl-, O-(5,6,7,8-tetrahydro-2-naphthalenyl) Ester
55. Smr002204143
56. Ft-0630959
57. L0301
58. D01550
59. Ab01566849_01
60. 678l313
61. Sr-01000872646
62. Sr-01000872646-1
63. Q27167100
64. (6-methoxy-2-pyridinyl)-methylcarbamothioic Acid
65. O-(5,6,7,8-tetrahydronaphthalen-2-yl) (6-methoxypyridin-2-yl)methylthiocarbamate
66. O-5,6,7,8-tetrahydronaphthalen-2-yl 6-methoxypyridin-2-yl(methyl)carbamothioate
67. (6-methoxypyridin-2-yl)(methyl)carbamothioic Acid O-(5,6,7,8-tetrahydronaphthalen-2-yl) Ester
| Molecular Weight | 328.4 g/mol |
|---|---|
| Molecular Formula | C18H20N2O2S |
| XLogP3 | 4.9 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 4 |
| Exact Mass | 328.12454906 g/mol |
| Monoisotopic Mass | 328.12454906 g/mol |
| Topological Polar Surface Area | 66.7 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 407 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
A Liranaftate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Liranaftate, including repackagers and relabelers. The FDA regulates Liranaftate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Liranaftate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Liranaftate supplier is an individual or a company that provides Liranaftate active pharmaceutical ingredient (API) or Liranaftate finished formulations upon request. The Liranaftate suppliers may include Liranaftate API manufacturers, exporters, distributors and traders.
click here to find a list of Liranaftate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Liranaftate Drug Master File in Japan (Liranaftate JDMF) empowers Liranaftate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Liranaftate JDMF during the approval evaluation for pharmaceutical products. At the time of Liranaftate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Liranaftate suppliers with JDMF on PharmaCompass.
Liranaftate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Liranaftate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Liranaftate GMP manufacturer or Liranaftate GMP API supplier for your needs.
A Liranaftate CoA (Certificate of Analysis) is a formal document that attests to Liranaftate's compliance with Liranaftate specifications and serves as a tool for batch-level quality control.
Liranaftate CoA mostly includes findings from lab analyses of a specific batch. For each Liranaftate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Liranaftate may be tested according to a variety of international standards, such as European Pharmacopoeia (Liranaftate EP), Liranaftate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Liranaftate USP).
LOOKING FOR A SUPPLIER?
